uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Essential thrombocythaemia treatment options: addressing patient-specific needs
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. (Hematologi)
2007 (English)In: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 79, no s68, 27-31 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2007. Vol. 79, no s68, 27-31 p.
Keyword [en]
essential thrombocythaemia, myeloproliferative disorders, treatment, risk assessment, leukaemia, hydroxyurea, anagrelide, interferon, adverse effects
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-11424DOI: 10.1111/j.1600-0609.2007.00941.xISI: 000248977100009PubMedID: 17727563OAI: oai:DiVA.org:uu-11424DiVA: diva2:39193
Note
Conference Information: Outflow form New Horizons in Haematology Meeting Sheffield, ENGLAND, MAR 09-10, 2007 Available from: 2007-09-13 Created: 2007-09-13 Last updated: 2017-12-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Medical Sciences
In the same journal
European Journal of Haematology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 377 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf